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A member of the Trk family of neurotrophin receptors, tropomyosin receptor kinase B (TrkB, 
encoded by the NTRK2 gene) is an increasingly important target in various cancer types, including 
glioblastoma (GBM). EGFR is among the most frequently altered oncogenes in GBM, and EGFR 
inhibition has been tested as an experimental therapy. Functional interactions between EGFR and 
TrkB have been demonstrated. In the present study, we investigated the role of TrkB and EGFR, 
and their interactions, in GBM. Analyses of NTRK2 and EGFR gene expression from The Cancer 
Genome Atlas (TCGA) datasets showed an increase in NTRK2 expression in the proneural subtype 
of GBM, and a strong correlation between NTRK2 and EGFR expression in glioma CpG island 
methylator phenotype (G-CIMP+) samples. We showed that when TrkB and EGFR inhibitors were 
combined, the inhibitory effect on A172 human GBM cells was more pronounced than when either 
inhibitor was given alone. When U87MG GBM cells were xenografted into the flank of nude mice, 
tumor growth was delayed by treatment with TrkB and EGFR inhibitors, given alone or combined, 
only at specific time points. Intracranial GBM growth in mice was not significantly affected by 
drug treatments. Our findings indicate that correlations between NTRK2 and EGFR expression 
occur in specific GBM subgroups. Also, our results using cultured cells suggest for the first time 
the potential of combining TrkB and EGFR inhibition for the treatment of GBM. 
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Growth factor receptors constitute many current and potential targets for molecularly specific 
therapies in cancer. The epidermal growth factor receptor (EGFR), a member of the ERBB family 
of transmembrane receptor tyrosine kinase (RTK) family, frequently shows gene amplification and 
activating mutations that contribute to driving the growth of lung and colorectal cancers 
(Mitsudomi and Yatabe 2010). EGFR is the target of clinically used small molecule inhibitors 
including erlotinib and gefitinib and monoclonal antibodies including cetuximab and 
panitumumab (Arteaga and Engelman 2014). 
 EGFR is among the most frequently altered oncogenes in glioblastoma (GBM), with 57% 
of tumors analyzed by the The Cancer Genome Atlas Research Network (TCGA) showing 
amplification, mutation, rearrangement, or altered splicing (Brennan et al. 2013). GBM is the most 
aggressive type of primary malignant brain tumor. Current treatment based on combining surgical 
resection followed by radiotherapy and chemotherapy results in a median overall survival of less 
than 2 years (Stupp et al. 2005; Wen et al. 2008). To date, clinical trials with EGFR inhibitors in 
patients with GBM have failed to successfully improve outcomes (van den Bent et al. 2009; 
Vivanco et al. 2012). A proposed experimental strategy to reduce resistance and improve 
effectiveness has been to combine EGFR inhibitors with other targeted agents acting on pathways 
that crosstalk with EGFR signaling (Keller and Schmidt 2017; Roesler et al. 2010). 
 EGFR has been shown to functionally interact with tropomyosin receptor kinase B (TrkB, 
encoded by the NTRK2 gene), a member of the Trk family of neurotrophin receptors. 
Neurotrophins are secreted proteins importantly involved in central nervous system development, 
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neurogenesis, and neuronal survival and plasticity (Park and Poo, 2013). Increasing evidence 
indicates that cancers can hijack neurotrophin signaling systems to promote tumor progression and 
resistance to treatment (Roesler et al. 2011; Thiele et al. 2009). In colorectal cancer cells, TrkB 
activation by its endogenous ligand, brain-derived neurotrophic factor (BDNF), promotes 
resistance against the EGFR inhibitor cetuximab, whereas co-treatment with TrkB and EGFR 
inhibitors reduce cell viability (de Farias et al. 2012). 
 GBM tumors express BDNF and TrkB, and TrkB activation enhances the viability of brain 
tumor stem cells (BTSCs) from human GBMs, whereas its inhibition reduces BTSC growth (Lawn 
et al. 2015). TrkB blockade also hinders viability of cultured human GBM cells (Pinheiro et al. 
2017). BDNF secreted by more differentiated GBM cells supports the growth of TrkB-expressing 
GBM BTSCs (Wang et al. 2018). NTRK gene fusions are currently established as oncogenic 
drivers of various adult and pediatric tumor types, and larotrectinib, a first-in-class small molecule 
Trk inhibitor, has received approval for patients with solid tumors harboring NTRK fusions (Cocco 
et al. 2018; Drilon et al. 2018). A gene fusion involving NTRK2 has been found to confer 
distinctive morphology and an aggressive phenotype in a case of low-grade glioma (Jones et al. 
2019). 
 Here, we investigated the role of TrkB and EGFR in GBM. First, we show data on the 
expression of NTRK2 and correlations with EGFR expression in GBM tumors from The Cancer 
Genome Atlas (TGCA) datasets. We then went on to examine the effects of inhibiting EGFR and 
TrkB receptors, either alone or in combination, in experimental models of GBM.  
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Materials and Methods 
 
NTRK2 and EGFR Expression Profiling in TCGA GBM Datasets 
 
NTRK2 expression levels were examined in previously described The Cancer Genome Atlas 
(TCGA n= 631 samples) GBM dataset and TCGA Lower Grade Glioma and Glioblastoma (n= 
702 samples) dataset. We used the data from gene expression array (platform: AffyU133a, version: 
2017-09-08), gene expression RNAseq (platform: IlluminaHiSeq, version: 2017-09-08) and copy 
number (type: gene-level GISTIC2 thresholded, version: 2017-09-08), data were obtained from 
the University of California–Santa Cruz Xena Public Data Hubs website at http://xena.ucsc.edu/. 
We analyzed the expression levels of NTRK2 regarding primary disease, primary tumor and 
recurrent samples, cytosine-phosphate-guanine (CpG) island methylator phenotype (G-CIMP), 
TCGA molecular subtypes, and the correlation with EGFR expression and amplification. 
Additionality, we evaluated the correlation between gene expression levels of NTRK2 with patient 
survival outcomes. 
 
Cell Culture  
 
Human GBM cells A172 and U87MG were obtained from American Type Culture Collection 
(Rockville, MD, USA)  and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) low 
glucose  supplemented with 10% fetal bovine serum (FBS, Gibco® by Thermo Fisher Scientific, 
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Life Technologies, Brazil), 1% penicillin/streptomycin and 0.1% fungizone® (250 mg/kg; 
Invitrogen Life Technologies, São Paulo, Brazil). Cells were maintained in a humidified 
atmosphere at 37°C and 5% CO2. 
 
Drug Treatments  
 
Selective antagonists of TrkB (ANA-12) and EGFR (Tyrphostin AG 1478) were obtained from 
Sigma Aldrich (St. Louis, MO). ANA-12 was diluted in dimethyl sulfoxide (DMSO) in a stock 
solution of 6140 µM and AG 1478 was diluted in ethanol (EtOH) in a stock solution of 3167 µM. 




After confluence, A172 and U87MG cells were trypsinized, placed in 96‐well plates at an initial 
density of 5.0 × 103 cells per well and after 24h the medium was replaced by increasing 
concentrations of ANA-12 (0, 1, 10, 20, 30 and 50 µM), AG- 1478 (0, 1, 5, 10, 20 and 30 µM) and 
also combinations of both inhibitors for 24, 48 or 72 h , while the control cells were maintained in 
DMSO or  EtOH when the treatments were used alone or a vehicle solution (DMSO plus EtOH) 
when the treatments were used in combination. In any of the situations the vehicles used did not 
exceed the concentration of 1% (v/v). The effect on cell cytotoxicity was evaluated using the trypan 
blue exclusion method in the Neubauer chamber (de Farias et al. 2012; Thomaz et al. 2016). All 
assays were performed in triplicate and repeated in three independent sets. 
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To assess cell cycle, GBM cells were cultured in 12-well plates under the same conditions as 
described above and after 24 h of exposure to treatments cells were detached, centrifuged and 
washed with PBS twice. The cells were then resuspended in 50 μg/ml propidium iodide (Sigma-
Aldrich, St. Louis, Mo., USA) in 0.1% Triton X-100 in 0.1% sodium citrate solution and incubated 
on ice and protected from light for 15 min. The cells were analyzed by flow cytometry (Attune® 





Experimental procedures for  the subcutaneous xenograft GBM model were performed in 
accordance with the Brazilian Guidelines for the Care and Use of Animals in Research and 
Teaching [DBCA, published by National Council for the Control of Animal Experimentation 
(CONCEA), and approved by the institutional Animal Care Committee (Comissão de Ética no 
Uso de Animais CEUA, Hospital de Clínicas de Porto Alegre-HCPA), under protocol number 
20160098. Animal experiments for the orthotopic xenograft GBM model were carried out under 
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Animals and Tumor Xenografts 
 
Balb/c nude mice (6 to 12 weeks old) were obtained from the University Hospital Animal Research 
Facility (UEA, CPE-HCPA) or from Charles River Laboratories. Animals were housed four per 
cage and kept under aseptic conditions in ventilated cages, maintained on a 12 h light/dark cycle 
at a room temperature of 22 ± 2°C. They were allowed ad libitum access to standardized pellet 
food and water. For the ex-vivo pharmacological inhibition, U87MG cells were cultured in 75 cm2 
or 175 cm2 culture flasks and treated with 13.85 µM of ANA-12, 13.26 µM of AG 1478 (alone or 
in combination) or vehicle (DMSO plus EtOH) for 24 h. A total of 1 × 106 viable cells were 
processed in serum-free DEMEM and diluted 1:1 with Matrigel (Corning, Corning, USA) and then 
injected subcutaneously (s.c) into the right flank of nude mice (6-8 mice per group). Measurements 
started five days after cells inoculation, when tumors reached approximately 40-75 mm3. The 
dimensions, length (L) and width (W), of the resulting tumors were determined every two days 
using a manual caliper, and the tumor volume (mm3) was calculated using the formula:  tumor 
volume = [length2 x width/2]. When tumors reached the endpoint (800-1000 mm3) mice were 
euthanized, and the tumors were excised, measured, and weighed. 
 For the orthotopic xenograft model, mice were anesthetized with isoflurane (4% oxygen) and 
placed in a stereotactic platform. The tops of the heads were disinfected, and a small incision was 
made in the scalp over the midline. A burr hole was made in the skull to a position 2 mm posterior 
and 1.5 mm lateral to the bregma in the right cerebral hemisphere. Next, mice were injected with 
40,000 U87MG cells processed in serum-free DMEM in a volume of 2 µl using an injector syringe 
pump. The burr hole in the skull was closed with sterile bone wax and veterinary tissue glue was 
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used to seal the incision. After surgery, the mice were placed in a recovery cage set to 37 °C until 
the animal recovered consciousness. Mice were monitored daily for signs of sickness, pain or 
weight loss. Seven days followed the surgery the animals were randomized into 4 groups (n=5 per 
group) to receive intraperitoneal (i.p.) injections for 21 days, and were treated by a blinded 
investigator with ANA-12 (1 mg/kg/daily plus vehicle for AG1478 every 3 days), AG1478 (10 
mg/kg every three days plus vehicle for ANA-12 daily), ANA-12 (1 mg/kg daily) plus AG 1478 
(10 mg/kg every three days). Control animals received ANA-12 and vehicle (DMSO 2% in saline 




Administration of 5-aminolevulinic acid (5-ALA), that leads to the synthesis and accumulation of 
fluorescent protoporphyrin IX (PPIX), has been used with fluorescence-guided surgery to directly 
visualize high-grade gliomas. After 21 days of treatment, the animals received an i.p. injection of 
5-ALA; 50 mg/kg and after 1 hour the mice were euthanized by cervical dislocation and the brains 
were removed to be analyzed. The IVIS system was used to record the ex-vivo fluorescent signal 
from tumors. First, we imaged the whole brains and next we used a brain matrix to cut sequential 
1 mm slices, in order to improve fluorescence detection, and the slices were also imaged.  Data 
acquisition and analysis was performed with Living Image software (Caliper LS living image 
version: 4.5.2.18424-september 11 2015, camera: IS1621N6980, Andor, iKon). In radiant 
efficiency mode, the wavelengths for emission and excitation were 620 and 420 respectively, and 
fixed size of regions of interest (ROIs) were drawn covering the whole tumor. The fluorescent 
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Statistical analysis of gene expression in two or more groups from the TCGA transcriptome 
datasets were performed using Welch's t-test and Kruskal-Wallis test for significance and Dunn’s 
tests for post hoc comparisons, respectively. Correlation analysis were performed by the Pearson 
correlation method. Survival distribution was estimated according to the Kaplan–Meier method 
using a median cut-off and log-rank statistics. These analyses were executed using the Graphpad 
8.0 software. Significant differences were revealed by p values below 0.05.  
 Experimental data were expressed as mean ± SEM. In vitro and in vivo experiments were 
analyzed using the GraphPad Prism software package, v. 5.0 (GraphPad, San Diego, CA). The 
level of significance between different experimental groups was performed using analysis of 
variance (ANOVA) followed by appropriate post-hoc tests; p < 0.05 was considered statistically 
significant. A drug combination analysis was performed based on the 50% inhibitory concentration 
(IC50) of the treatments. For calculation of IC50 data were fitted in a dose response curve 
(Graphpad Prism v. 5.0) using the equation Y=100/(1+10^((X-LogIC50))). The interaction 
between ANA-12 and AG-1478 was assessed by the combination index method (Cl) (Chou and 
Talalay 1984). Synergism, addition and antagonism between drug combinations were defined as 
CI < 0.9, CI = 0.9-1.1 and CI > 1.1, respectively.  
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NTRK2 Expression Levels are Increased in Lower Grade Glioma, Proneural GBM 
Subtype and GBM Methylated Phenotype in GBM Patients 
 
We evaluated TCGA GBM datasets to explore whether NTRK2 expression correlates with EGFR 
expression, GBM subtype and patient survival. First, we classified TCGA samples by primary 
disease type between lower grade glioma (LGG) and GBM, based on array data available for 702 
samples. NTRK2 expression was increased in LGG in comparison to GBM samples (Fig. 1A, p < 
0.0001). We also evaluated the levels of NTRK2 across normal brain samples, primary and 
recurrent tumors, however, no statistical differences were observed between these groups (Fig. 1B, 
p = 0.220). Based on the definition of GBM molecular subtypes, we found that NTRK2 expression 
was lower in the mesenchymal subtype when compared with neural and proneural subtypes (Fig. 
1C, p < 0.01). NTRK2 expression was highest in the proneural group in comparison with classical 
and mesenchymal subtypes (Fig. 1C, p < 0.0001). Given that the proneural group is associated 
with IDH mutations and IDH-mutant gliomas manifest the cytosine-phosphate-guanine (CpG) 
island methylator phenotype (G-CIMP), we evaluated the expression of NTRK2 regarding the 
methylation phenotype between G-CIMP+ and G-CIMP-. We observed an increased expression of 
NTRK2 in G-CIMP+ samples (Fig. 1D, p < 0.01), which is consistent with the increased expression 
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Correlations between NTRK2 and EGFR Expression in GBM Tumors 
 
To analyze whether the NTRK2 expression correlates with EGFR levels, we performed correlation 
analysis across samples registered with TCGA dataset. We detected a weak correlation between 
NTRK2 and EGFR expression when considering all GBM samples together (Fig. 1E, correlation 
= 0.1603, p = 0.0002) and G-CIMP GBM samples (Fig. 1G, correlation = 0.1869, p = 0.0001). A 
moderate correlation between NTRK2 and EGFR expression was found in G-CIMP+ samples (Fig. 
1F, correlation = 0.3443, p = 0.0221). 
 We also determined the relationship between NTRK2 expression and patient overall 
survival (Fig. 1H), using median of NTRK2 expression as a cutoff between low and high 
expression. We further looked at the effect of NTRK2 expression in patients stratified by EGFR 
amplification (Fig. 1I). Survival of GBM patients was not significantly different when tumors with 
high and low NTRK2 expression levels were compared. 
 
 
Figure 1 should be inserted here 
 
 
Selective Inhibition of TrkB and EGFR Decreases GBM Cell Viability 
 
To examine the effects of TrkB and EGFR inhibition on cell viability, GBM cells were treated 
with ANA-12 and AG 1478 alone or in combination and viability was assessed by the trypan blue 
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exclusion method. Time course analysis showed that both single treatments decreased A172 and 
U87MG cell viability when compared with control cells treated with vehicle (p < 0.001). The 
effect was observed in A172 cells after 48 hours of treatment with ANA-12 at 10 μM or AG1478 
at 30 μM (Fig. 2A, 2B). A similar effect was observed in U87MG cells after 24 hours of treatment 
with the dose of 10 μM of ANA-12 or AG1478 (Fig. 2C, 2D).  We also analyzed whether the 
reduction of cell viability with ANA-12 or AG1478 were dose-dependent. As depicted in Fig. 2, 
both treatments showed features of dose-dependent effect in A172 and U87MG cells. After time 
course and dose-response curves analysis, we defined proper doses and time to evaluate the effect 
of the combination (ANA-12 plus AG1478) on cell viability. When the two drugs were combined 
the inhibitory effect was more pronounced in A172 cells compared to either IC50-equivalent 
isolated drugs and in the combination of both drugs in higher doses (see Fig. 2I for detailed results 
and p values for specific comparisons). In contrast, the effect of the combination treatment was 




Figure 2 should be inserted here 
 
 
Pharmacological Interactions between TrkB and EGFR Inhibitors 
 
In order to evaluate drug interaction effects, IC50-values were calculated from the effects seen in 
the cytotoxicity assay (Fig. 3). ANA-12 had IC50 values of 10.0 (7-14) μM and 13.85 (11-17) μM 
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for A172 and U87MG cells, respectively. IC50 values of AG1478 were 20.0 (16-21) μM for A172 
cells and 13.26 (11-16) μM for U87MG cells (Fig. 3A). Pharmacological interactions of the 
combined treatment with ANA-12 and AG1478 were investigated using cytotoxicity as the chosen 
outcome and evaluated by Chou-Talalay method (Chou and Talalay 1984). Synergism, addition 
and antagonism for drug combinations was defined as CI < 0.9, CI = 0.9-1.1 and CI > 1.1, 
respectively.  We observed synergy in A172 cells (CI = 0.75). However, in U87MG cells the 
inhibitors presented antagonism, as shown by the combination index value of 2.2 (Fig. 3B). 
 
 
Figure 3 should be inserted here 
 
 
TrkB and EGFR Inhibitors Induce Changes in Cell Cycle Features of GBM Cells 
 
Effects on cell cycle were evaluated by flow cytometry after treatment with ANA-12 and AG 1478 
alone or in combination in GBM cells. As shown in Fig. 4, the TrkB inhibitor induced a significant 
reduction in S phase, which starts at the dose of 10 μM and persists at a dose of 20 μM in A172 
cells (Fig. 4A p < 0.001 and p < 0.0001, respectively). The reduction of S phase due to TrkB 
inhibition was also observed in U87MG cells, but only at the dose of 50 μM (p < 0.05, Fig. 4D). 
Treatment with 30 μM of AG 1478 significantly increased the number of A172 and U87MG cells 
in G0/G1 phase when compared with control cells (Fig. 4B, 4E, p < 0.01 and p < 0.05, 
respectively).  The combined treatment lead to a combination of effects leading to both 
accumulation of cells in G0/G1 and reduction of S phase in A172 cells (Fig. 4C p < 0.05 and p < 
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0.01). The combined treatment did not cause significant changes in the cell cycle of U87MG cells; 
however, we could observe a small percentage of cells in Sub-G1 phase when compared with 
controls (Fig. 4F, p < 0.05). 
 
 
Figure 4 should be inserted here 
 
 
Long-term Effects of TrkB and EGFR Inhibition in a GBM Xenograft Mouse Model 
 
To explore the roles of EGFR and TrkB during tumorigenesis, we used a preclinical subcutaneous 
xenograft GBM model. U87MG cells were treated with ANA-12, AG 1478, ANA-12 plus AG 
1478 and DMSO or EtOH. After 24 h, the animals were randomized and viable pre-treated U87MG 
cells were injected subcutaneously into the right flank of mice (Fig. 5A). Fig. 5B illustrates tumor 
volume size across different days. Tumor size was significantly different in day 15 in all treatment 
groups when compared with controls given vehicle. Mice that received cells treated with ANA-
12, alone or combined with AG 1478, also showed smaller tumors at day 31. The apparent 
reduction in tumor size in all drug-treated groups compared to controls at day 45 did not reach 
statistical significance (Fig. 5C). When tumors reached 800-100 mm3 the mice were euthanized, 
and the tumors were excised, and weight and volume were determined. Ex-vivo tumor analysis 
showed an apparent reduction in tumor volume when compared treatment groups with control, 
however, these differences did not reach statistical significance (Fig. 5D). Moreover, there were 
no statistically significant differences among groups regarding tumor weight (Fig. 5E). We also 
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evaluated possible differences in survival comparing treatment groups with control group. 
Although the median survival days of the control group (38 days) was lower when compared to 
treatment groups (ANA-12, 45 days; AG 1478, 41 days; ANA-12+AG 1478, 44 days), no 
statistically differences were observed (Fig. 5F). 
 
 
Figure 5 should be inserted here 
 
 
Effects of Combined TrkB and EGFR Inhibition on Intracranial GBM Tumor Growth 
 
We tested the hypothesis that the combined inhibition of TrkB plus EGFR would inhibit the growth 
of intracranial GBM in mice. Seven days after inoculation of U87MG cells, mice were randomized 
to receive i.p. injections in a period of 21 days with ANA-12 (1 mg/kg daily plus vehicle every 3 
days), AG1478 (10 mg/kg every three days plus vehicle daily), ANA-12 (1 mg/kg daily) plus AG 
1478 (10 mg/kg every three days) and vehicle daily (Fig. 6A). During the treatment period, mice 
were monitored daily for any signs of sickness, pain or weight loss. The tumor growth was 
analyzed by ex-vivo brain fluorescent imaging of the different groups using the IVIS system after 
29 days after cell inoculation. Tumor fluorescence did not reveal a significant difference among 




.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a










Gene expression analysis in GBM tumor datasets showed an increased NTRK2 expression in 
proneural, G-CIMP+ GBMs. Interestingly, significant correlations between NTRK2 and EGFR 
expression levels were found in GBM, particularly in G-CIMP+ tumors. Previous analyses of 
TCGA GBMs have shown that G-CIMP+ glioblastomas presented reduced mRNA levels for 
EGFR due to epigenetic regulation (Li et al. 2014). The proneural G-CIMP phenotype confers a 
survival advantage for GBM patients (Brennan et al. 2013), and its possible relationship with 
NTRK2 expression revealed here warrants further exploration. 
One of the main findings in the present study was that the combined inhibition of TrkB and 
EGFR was more pronounced than either treatment given alone in impairing GBM cell viability. 
This result is consistent with the view that TrkB inhibition may sensitize cancer cells to the effects 
of EGFR inhibitors (Roesler et al. 2011). ANA-12, originally developed as an experimental 
antidepressant, selectively and efficiently inhibits TrkB by binding to both low- and high-affinity 
sites on the receptor extracellular domain (Cazorla et al. 2011). AG 1478 is a selective EGFR 
inhibitor that shares a structural quinazoline main chain with the clinically used EGFR inhibitors 
gefitinib and erlotinib (Ellis et al. 2006). The results observed with these two small-molecule 
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compounds in two different mouse GBM xenograft models were less clear. When cells were 
pretreated with drug treatments before being xenografted into the flanks of nude mice, treatments 
were able to slow tumor growth only at specific time points (15 and 31 days after cell inoculation), 
but drug-treated tumors were able to reach sizes comparable to controls by the end of the follow-
up period. In addition, treatments did not significantly change tumor progression assessed by 
fluorescence in mice receiving GBM cells intracranially followed by systemic drug treatments. 
Given the potency of ANA-12 and AG1478 inhibition of cell viability in vitro, we expected to 
observe pronounced drug effects in in vivo models. A possible limitation was measuring 
fluorescence only at the end of treatment rather than at different time points during treatment. 
Importantly, EGFR may have a dual role, contributing to tumor progression but also conferring 
increased DNA damage response and high sensitivity to the inhibitor talazoparib (Wu et al. 2019). 
Thus, differential roles of EGFR signaling could occur under the different experimental conditions 
we used (for example, regulation by the tumor microenvironment in in vivo assays), resulting in 
contrasting findings. The lack of effects may also be related to the choice of drug doses in our 
experiments. The drug doses and treatment regimens we used for in vivo experiments were based 
on previous studies that used xenograft models of other cancer types (Thomaz et al. 2019; Yu et 
a. 2014). It is still possible that, as suggested by our results shown in Fig. 3, the two drugs used 
show antagonistic activity in U87MG cells. Another point worth mentioning is that, together, the 
results obtained in our in vitro and flank xenograft experiments might suggest that TrkB and EGFR 
inhibition can delay GBM growth in the short-term, but not after longer delays, when tumors are 
able to recover full growth.    
  GBM differentiated cells have been shown to secrete BDNF to stimulate TrkB in GBM 
stem cells and induce them to secrete nerve growth factor inducible (VGF), a neuropeptide that 
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promotes survival and growth of GBM stem-like and differentiated cells (Wang et al. 2018). TrkB 
knockdown or pharmacological inhibition of TrkB hinders BDNF-dependent GBM stem-like cell 
growth (Lawn et al. 2015). TrkB-containing exosomes promote the transfer of aggressiveness 
between GBM cells (Pinet et al. 2016). EGFR inhibition has been proposed as a therapeutic 
strategy in GBM and has been tested in preclinical (Buendia Duque et al 2019; Parker et al. 2013; 
Zahonero et al. 2015) and clinical (Makhlin et al. 2019; Sepúlveda-Sánchez et al. 2017), with 
mixed results. One previous study examined the interaction between TrkB and EGFR in 
experimental GBM and showed that stimulation of neurotrophin signaling can overcome the 
inhibitory effects of EGFR inhibition on GBM cell growth (Lawn et al. 2015). The present study 
is the first one to verify whether the combined inhibition of TrkB and EGFR may effectively reduce 
GBM growth.      
In summary, analysis of TCGA tumors showed that correlations between NTRK2 and 
EGFR expression can be observed in GBM, and the role of TrkB and EGFR in the proneural, G-
CIMP+ subtype of GBM should be further investigated by future studies. In addition, our results 
using cultured cells indicate for the first time the potential of combining TrkB and EGFR inhibition 
for the treatment of GBM, however we could not observe pronounced effects in vivo.     
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Legends for figures 
 
Fig 1 NTRK2 expression and its correlation with EGFR expression levels in TCGA GBM datasets. 
Transcript levels of NTRK2 were examined in previously described transcriptome datasets from 
the TCGA GBM dataset (n=631 samples) and the TCGA Lower Grade Glioma (LGG) and GBM 
(n=702 samples) dataset. (A) Expression levels of NTRK2 in LGG and GBM patient cohorts. (B) 
Normal brain, primary and recurrent GBM samples. (C) GBM subtypes. (D) cytosine-phosphate-
guanine (CpG) island methylator phenotype (G-CIMP). Data was presented in violin plot format 
as log2-transformed signal intensity and statistical analyses were performed using Kruskal-Wallis 
test followed by Dunn’s post hoc tests, * p<0.05; ** p<0.01; *** p<0.001 and **** p<0.0001 for 
significance. (E, F, G) Correlation between NTRK2 and EGFR expression levels in the TCGA 
GBM dataset. Pearson correlation coefficients and their p values were calculated using GraphPad 
prism. Trend lines were determined by the linear regression model. Overall survival probability in 
a set of 523 samples from the TCGA GBM cohort. (H) all samples and (I) EGFR amplified 
samples. Patients were grouped according to low or high expression of NTRK2. Survival 
distribution was estimated according to the Kaplan-Meier method using median cut-off selection 
and log-rank statistics. 
 
Fig 2 Inhibition of TrkB and EGFR alone or in combination reduces human GBM cell viability. 
Time course analysis of cell viability, by trypan blue cell counting, were performed after 24, 48 
and 72 h of exposure to ANA-12 or AG 1478 exposure in A172 (A, B) and U87MG (C, D) cells. 
Dose-response curves were evaluated by trypan blue cell counting after treatment with increasing 
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concentrations of ANA-12 (1-50µM) or AG 1478 (1-30 µM) for 48 h in A172 cells (E, F) and 24 
h in U87MG cells (G, H). The drug vehicles (DMSO or EtOH) served as controls. Dose-response 
curves after combined treatment with ANA-12 and AG 1478 were evaluated after 48 h of drug 
exposure in A172 cells (I) and 24 h in U87MG cells (J). Data are expressed by mean ± SEM and 
represent three independent experiments *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
compared to control cells; # p<0.05 and ### p<0.001 compared to ANA-12; ++ p<0.01 and +++ 
p<0.001 compared with AG 1478; one-way ANOVA followed by Tukey tests for multiple 
comparisons). 
 
Fig 3 Synergistic effect after combined inhibition of TrkB and EGFR in A172 GBM cells. A172 
and U87MG cell lines were treated with varying concentrations of ANA-12 and AG 1478 alone 
or in combination. The IC50-values were calculated from the dose-response curves after different 
exposure times (48 h for A172 and 24 h for U87MG cells) and expressed with their respective 
95% confidence intervals and summarized in the table (A). The combination index (CI) was 
determined by the method of Chou-Talalay and data are presented as mean ± SEM (B). 
 
Fig 4 Effects of EGRF and TrkB inhibition on GBM cell cycle. Cells were exposed to ANA-12, 
AG 1478 or ANA-12 plus AG 1478 for 24 h, and the percentages of cells in G0/G1, S and G2/M 
phases of the cell cycle were evaluated. Two wells were assigned to each treatment and the 
experiments were repeated at least three times. Data are presented as mean ± SEM of the 
percentage of cells in each phase. * p <0.05; ** p <0.01; *** p<0.001 and **** p<0.0001 
compared to the respective control group, one-way ANOVA followed by the Dunnett test (a,b). 
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Fig 5 Inhibition of TrkB and EGFR alone or in combination in a subcutaneous GBM xenograft 
mouse model. U87MG cells were pretreated in vitro for 24 h with ANA-12 (13.85 μM), AG-1478 
(13.26 μM) or ANA-12 plus AG-1478, and the viable cells were injected into the flanks of nude 
mice (6-7 mice per group) as shown in the schematic drawing (A).  Caliper measurements were 
used to determine the displayed subcutaneous tumor volume. Mice were euthanized and tumors 
were excised when volume reached approximately 800-1,000 mm3 (B) Tumors were measured 
every 2 days and volumes were calculated as described in materials and methods section. Tumor 
growth is represented by tumor volume (mm3) at the indicated days; Control (n= 7), ANA-12 (n= 
8), AG 1478 (n= 8) and ANA-12 plus AG 1478 (n= 8) (C) Tumor growth curve is shown on 
selected time points of 15, 31 and 45 days to highlight statistical differences (D). Tumor volumes 
(mm3) at the time of tissue harvest. (E) Tumor weight (mg) at the time of tissue harvest are shown 
in (F) Kaplan-Meier curves presenting percent of mice surviving following tumor implantation. 
Data are expressed as mean ± SEM (* p<0.05; ** p<0.01). Statistical analysis was performed using 
one-way ANOVA followed by Tukey’s post-hoc tests. 
 
Fig 6 Inhibition of TrkB and EGFR in an intracranial GBM mouse model. (A) A total of 40,000 
U87MG cells were intracranially (i.c.) injected into nude mice. Drug treatments started on the 
seventh day after cell implantation. The animals were randomly divided in 4 groups (n=5 per 
group) to receive intraperitoneal (i.p.) injections for 21 days, and were treated by a blinded 
investigator with ANA-12 (1 mg/kg daily plus vehicle every 3 days), AG1478 (10 mg/kg every 
three days plus vehicle daily), ANA-12 (1 mg/kg daily) plus AG 1478 (10 mg/kg/every three days) 
and vehicle (DMSO) daily. After 21 days of treatment, the animals received an i.p. injection of 5-
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted February 4, 2020. . https://doi.org/10.1101/2020.02.03.932608doi: bioRxiv preprint 
30 
 
ALA (50 mg/kg) and after 1 h mice were euthanized by cervical dislocation and the brains were 
removed to be analyzed  (B) Representative IVIS images of harvested brains acquired at day 29 
after transplantation. (C) Corresponding data of 5-ALA (PPIX) radiant efficiency from the whole 
brain. (D) After performing images of the intact brain, a brain matrix was used to cut sequential 1-
mm slices through the region containing the tumor. Slices were imaged using IVIS and 
fluorescence images were collected. Data are expressed as mean ± SEM. Statistical analyses were 
performed using one-way ANOVA followed by Tukey’s post-hoc tests. No statistical differences 
were observed between experimental groups. 
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